Sugammadex

Generic Name: Sugammadex

Brand Names: Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal

Drug Type: Small Molecule

Chemical Formula: C_₇₂H_₁₁₂O_₄₈S_₈

CAS Number: 343306-71-8

Unique Ingredient Identifier: 361LPM2T56

Background: Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.

Indication: Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.

Associated Conditions: Neuromuscular blockade caused by vecuronium bromide

Associated Therapies: -

Clinical Trials

Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex

Phase 4

Conditions: Diaphragm Ultrasonography
Liver Dysfunction
Sugammadex
Rocuronium

Interventions: Drug: sugammadex

First Posted Date: 2021-08-31

Last Posted Date: 2021-09-05

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 99

Registration Number: NCT05028088

Locations: 🇨🇳
Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China

The Feasibility of Sugammadex for General Anesthesia in Patients Undergoing Kidney and Pancreas Transplantation Surgery

Not Applicable

Completed

Conditions: Surgery

Interventions: Drug: Sugammadex
Drug: Normal saline

First Posted Date: 2021-06-29

Last Posted Date: 2021-06-29

Lead Sponsor: Second Affiliated Hospital of Guangzhou Medical University

Target Recruit Count: 52

Registration Number: NCT04944303

Locations: 🇨🇳
The Second Affiliated Hospital,Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳
Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Reversal of Neuromuscular Blockade and Perioperative Arrhythmias

Not Applicable

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2021-01-22

Last Posted Date: 2021-01-22

Lead Sponsor: Başakşehir Çam & Sakura City Hospital

Target Recruit Count: 80

Registration Number: NCT04720573

Locations: 🇹🇷
Istanbul Medipol University, Istanbul, Turkey

Effect of Muscle Relaxation Reversal on the Success Rate of Motor Evoked Potential Recording

Not Applicable

Completed

Conditions: Sugammadex
Motor Evoked Potentials

Interventions: Drug: Sugammadex
Drug: Saline

First Posted Date: 2020-10-29

Last Posted Date: 2022-09-21

Lead Sponsor: Beijing Tiantan Hospital

Target Recruit Count: 170

Registration Number: NCT04608682

Locations: 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China

Comparison of Time to Extubation Using Sugammadex or Neostigmine

Phase 4

Completed

Conditions: Neuromuscular Blockade
Chronic Obstructive Pulmonary Disease

Interventions: Drug: neostigmine/glycopyrrolate
Drug: sugammadex

First Posted Date: 2020-10-28

Last Posted Date: 2024-03-13

Lead Sponsor: Temple University

Target Recruit Count: 58

Registration Number: NCT04606901

Locations: 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States

Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine

Phase 4

Completed

Conditions: Anesthesia

Interventions: Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2020-09-30

Last Posted Date: 2024-04-15

Lead Sponsor: University of California, San Diego

Target Recruit Count: 90

Registration Number: NCT04570150

Locations: 🇺🇸
University of California San Diego, La Jolla, California, United States

Effectiveness of Sugammadex on Muscle Relaxant Reversal in Preterm Neonates

Not Applicable

Conditions: Sugammadex

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2020-09-28

Last Posted Date: 2020-09-28

Lead Sponsor: Alexandria University

Target Recruit Count: 60

Registration Number: NCT04566796

Locations: 🇪🇬
Alexandria university, Alexandria, Egypt

A Pharmacokinetic Study of Sugammadex in Dialysis Patients

Phase 1

Withdrawn

Conditions: Renal Disease

Interventions: Drug: Sugammadex

First Posted Date: 2020-09-21

Last Posted Date: 2021-09-17

Lead Sponsor: Tetsuro Sakai

Registration Number: NCT04556721

Locations: 🇺🇸
UPMC Montefiore Hospital, Pittsburgh, Pennsylvania, United States

Sugammadex To IMprove Bowel Function

Phase 4

Completed

Conditions: Bowel Dysfunction
Postoperative Complications
Neuromuscular Blockade

Interventions: Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2020-09-14

Last Posted Date: 2024-07-29

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 120

Registration Number: NCT04546672

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Comparison of the Impacts of Sugammadex With Neostigmine on Patency of Laryngeal Opening (Glottic Aperture Angle)

Not Applicable

Conditions: Supraglottic Airway Device Insertion

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2020-09-10

Last Posted Date: 2020-09-10

Lead Sponsor: Yonsei University

Target Recruit Count: 84

Registration Number: NCT04545099

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy